E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: 66da67d533ba6d8c166b5bd754e6351053f7a45e
First added on: Feb 04, 2025